Assenagon Asset Management S.A. lowered its position in Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) by 45.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,831 shares of the company’s stock after selling 13,220 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Protara Therapeutics were worth $26,000 as of its most recent SEC filing.
Separately, Virtu Financial LLC bought a new position in shares of Protara Therapeutics during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 46.44% of the company’s stock.
Protara Therapeutics Trading Up 7.8 %
Shares of Protara Therapeutics stock opened at $2.89 on Friday. Protara Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $4.18. The stock’s fifty day moving average price is $2.05 and its 200-day moving average price is $1.90. The firm has a market cap of $32.83 million, a P/E ratio of -0.47 and a beta of 1.52.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
- Five stocks we like better than Protara Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- The 5 best small cap AI companies to buy now
- How to Invest in Renewable Energy
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- How to invest in marijuana stocks in 7 steps
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.